The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.

The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.

File Thomas M Jr

International journal of antimicrobial agents

2007

2007-12

Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.

Adult; Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use; Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use; Bacteria/*drug effects/isolation & purification; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/drug therapy/microbiology; Respiratory Tract Infections/*drug therapy/microbiology; Sinusitis/drug therapy/microbiology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

S131–134

30 Suppl 2